Denne siden ble automatisk oversatt og nøyaktigheten av oversettelsen er ikke garantert. Vennligst referer til engelsk versjon for en kildetekst.

Vaccination Response Modulation With a Targeted Rapamycin Protocol Study (VON TRAPP)

11. mai 2026 oppdatert av: Matthew Tunbridge, Central Adelaide Local Health Network Incorporated

Vaccination Response Modulation With a Targeted Rapamycin Protocol (VON TRAPP) Study

This study will investigate dialysis recipients' responses to important vaccines.

Research suggests that a medication commonly used by transplant recipients may improve vaccine responses. The investigators will be conducting a clinical trial to see whether a short course of low-dose Sirolimus improves the response to vaccination against respiratory syncytial virus (RSV) and influenza (flu) in patient with kidney disease over 60 years old who receive haemodialysis.

Studieoversikt

Status

Har ikke rekruttert ennå

Forhold

Intervensjon / Behandling

Detaljert beskrivelse

Respiratory viruses are a significant cause of morbidity and mortality in Australia. Respiratory syncytial virus (RSV) and Influenza are major contributors to yearly respiratory virus epidemics that particularly affect older persons and persons with end-stage kidney disease.

Vaccination is available for the prevention of both RSV and Influenza, but unfortunately the conditions that confer a higher risk of morbidity and mortality with infection are also key predictors of poor responses to vaccination.

Effective vaccine responses require activation of both T and B cells to generate protective and long-lasting antibody and cellular immune responses. Immunosenescence from ageing and end-stage kidney disease, dampens antibody responses and impairs cellular immunity, rendering patients vulnerable to infection.

Previous research suggests that sirolimus(rapamycin)-based immunosuppression regimens improve vaccine immunogenicity. Sirolimus (rapamycin) is a potent inhibitor of mTORC1 which regulates memory CD8+ T cells. Targeting mTORC1 has previous been shown to improve vaccination response in humans to influenza. More recently, small studies have suggested improved responses to COVID vaccination in kidney transplant recipients switched to sirolimus (rapamycin)-based regimens.

This study will investigate a role for sirolimus (rapamycin) as a peri-vaccination immune modulation therapy. The VON TRAPP study is a phase 2a randomised clinical trial that aims to define the optimal, practical and tolerable regimen of peri-vaccination sirolimus (rapamycin) administration to positively modify vaccine responses. Haemodialysis patients over 60 years old will receive both Influenza and RSV vaccines plus either no additional treatment or a peri-vaccination regimen of sirolimus (rapamycin) to determine the most effective regimen to test further.

Studietype

Intervensjonell

Registrering (Antatt)

60

Fase

  • Fase 2

Kontakter og plasseringer

Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.

Studiekontakt

Studer Kontakt Backup

Studiesteder

  • Australia
    • New South Wales
      • Camperdown, New South Wales, Australia, 2050
    • Queensland
      • Woolloongabba, Queensland, Australia, 4102
    • South Australia
      • Adelaide, South Australia, Australia, 5000
        • Royal Adelaide Hospital
        • Ta kontakt med:

Deltakelseskriterier

Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.

Kvalifikasjonskriterier

Alder som er kvalifisert for studier

  • Voksen
  • Eldre voksen

Tar imot friske frivillige

Nei

Beskrivelse

Inclusion Criteria:

  • End-stage kidney disease requiring in-centre haemodialysis three times per week as kidney replacement therapy
  • Aged >60 years

Exclusion Criteria:

  • Aged <60 years
  • Alternative haemodialysis regimens (e.g. twice-weekly haemodialysis, second-daily home haemodialysis)
  • Recent infection (<6 months) with proven Influenza A, Influenza B, or RSV

  • Current use of immunosuppressive medications, including:

    • Oral steroid at a dose equivalent of 5 mg/day prednisolone or greater
    • Mycophenolate mofetil
    • Azathioprine
    • Calcineurin inhibitors
    • mTOR inhibitors

  • Recent use of intravenous immunosuppressive medications (<6 months), including:

    • T-cell depleting agents (e.g. anti-thymocyte globulin)
    • B-cell depleting agents (e.g. rituximab)
    • Cyclophosphamide

  • Has a history of problems with side-effects associated with sirolimus use including

    • Angioedema
    • Active/recent opportunistic infection
    • Current or prior interstitial lung disease, non-infectious pneumonitis, organising pneumonia, or pulmonary fibrosis
    • Clinically significant pleural effusion or pericardial effusion
    • Active non-healing wounds, chronic skin ulcers, or planned major surgery/procedures
    • Current malignancy or recent malignancy with high recurrence risk
    • Severe or uncontrolled hyperlipidaemia
    • History of rhabdomyolysis
    • Severe hepatic impairment

  • Ongoing use of strong CYP3A4/P-gp inhibitors or inducers including

    • Inhibitors: Ketoconazole, Voriconazole, Itraconazole, Telithromycin, Clarithromycin
    • Inducers: Rifampicin, Rifabutin
  • Unable or unwilling to provide informed consent to participate in the trial
  • Known allergy to or intolerance of sirolimus (rapamycin) or the contents of the influenza or RSV vaccine

Studieplan

Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.

Hvordan er studiet utformet?

Designdetaljer

  • Primært formål: Forebygging
  • Tildeling: Randomisert
  • Intervensjonsmodell: Parallell tildeling
  • Masking: Ingen (Open Label)

Våpen og intervensjoner

Deltakergruppe / Arm
Intervensjon / Behandling
Aktiv komparator: Control
Influenza and RSV vaccination without additional treatment
Biologisk: Influenza vaccine (Sequiris Fluad Quad)
All participants will receive a dose of the seasonal Influenza vaccine (Sequiris Fluad Quad)
Biologisk: RSV vaccine (Pfizer Abrysvo)
All participants will receive a dose of the RSV vaccine (Pfizer Abrysvo)
Eksperimentell: Pre-vaccine sirolimus group
Sirolimus 2mg orally x3/week on haemodialysis for 3 weeks. Influenza and RSV vaccination 2 weeks after completing sirolimus course.
Biologisk: Influenza vaccine (Sequiris Fluad Quad)
All participants will receive a dose of the seasonal Influenza vaccine (Sequiris Fluad Quad)
Biologisk: RSV vaccine (Pfizer Abrysvo)
All participants will receive a dose of the RSV vaccine (Pfizer Abrysvo)
Legemiddel: Sirolimus (RAPAMUNE)
All treatment groups will receive 9 doses of 2mg sirolimus over a 3 week period, at varying times relative to vaccination.
Andre navn:
  • Rapamycin
Eksperimentell: Peri-vaccine sirolimus group
Sirolimus 2mg orally x3/week on haemodialysis for 3 weeks. Influenza and RSV vaccination 1 week after commencing sirolimus course.
Biologisk: Influenza vaccine (Sequiris Fluad Quad)
All participants will receive a dose of the seasonal Influenza vaccine (Sequiris Fluad Quad)
Biologisk: RSV vaccine (Pfizer Abrysvo)
All participants will receive a dose of the RSV vaccine (Pfizer Abrysvo)
Legemiddel: Sirolimus (RAPAMUNE)
All treatment groups will receive 9 doses of 2mg sirolimus over a 3 week period, at varying times relative to vaccination.
Andre navn:
  • Rapamycin
Eksperimentell: Post-vaccine sirolimus group
Sirolimus 2mg orally x3/week on haemodialysis for 3 weeks. Influenza and RSV vaccination 2 weeks prior to commencing sirolimus course.
Biologisk: Influenza vaccine (Sequiris Fluad Quad)
All participants will receive a dose of the seasonal Influenza vaccine (Sequiris Fluad Quad)
Biologisk: RSV vaccine (Pfizer Abrysvo)
All participants will receive a dose of the RSV vaccine (Pfizer Abrysvo)
Legemiddel: Sirolimus (RAPAMUNE)
All treatment groups will receive 9 doses of 2mg sirolimus over a 3 week period, at varying times relative to vaccination.
Andre navn:
  • Rapamycin

Hva måler studien?

Primære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Vaccine-specific functional T cell memory
Tidsramme: Six weeks post vaccination
The change in functional T cell memory from baseline to six weeks post vaccine dose, measured as IFN-γ spot-forming units (SFU) by ELISpot following 18-hour stimulation of PBMCs with RSV peptides.
Six weeks post vaccination

Sekundære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Cellular immune response to vaccination
Tidsramme: Six weeks post vaccination
RSV vaccine-specific cellular immunity, measured as 1) change in frequency of CD8+ RSV F protein-specific T cells from baseline to six weeks post vaccine dose, identified by flow cytometry as CD8+CD134+CD69+ following 24-hour stimulation with a protein-derived peptide array (AIM, Activation-Induced Marker assay); 2) Change in frequency of RSV F protein-specific polyfunctional T cells from baseline to six weeks post vaccine dose. Polyfunctional T cells are defined as CD4+ T cells that produce more than one of IFN-γ, IL-2 and TNF identified by flow cytometry intracellular cytokine staining following 24-hour stimulation with a protein-derived peptide array (ICS, Intracellular Cytokine Staining assay).
Six weeks post vaccination
Vaccine-specific humoral immune response
Tidsramme: Six week post vaccination
Measures of vaccine-specific humoral immunity, measured as 1) Anti-RSV F protein IgM, IgA and IgG antibody titres 6 weeks following the vaccine dose; 2) Change in haemagglutination inhibition (HAI) titre of influenza strains contained in the 2026 vaccine from baseline to six weeks post vaccination.
Six week post vaccination
Incidence of infection post-vaccination
Tidsramme: Twelve months post vaccination
Incidence of RSV or Influenza infection in the study cohort from 3 weeks post vaccination to 12-month follow-up
Twelve months post vaccination
Incidence of Sirolimus (Rapamycin) Treatment-Emergent Adverse Events [Safety and Tolerability]
Tidsramme: Six week post vaccination
Safety and tolerability of 3-week course of low-dose sirolimus (rapamycin), measured as frequency of adverse events (including serious adverse events)
Six week post vaccination
Incidence of Immunization Treatment-Emergent Adverse Events [Safety and Tolerability]
Tidsramme: Six weeks post vaccination
Safety and tolerability of vaccine regimen, assessed by 1. Frequency of adverse events following immunization (AEFI), including adverse events of special interest (AESI) such as recurrence of autoimmune disease
Six weeks post vaccination
Quality of life questionnaire
Tidsramme: Six weeks post-vaccination
Quality of life following 3-week course of low-dose sirolimus (rapamycin) and vaccination, measured with the EQ-5D-5L quality of life questionnaire. This questionnaire reports on 5 functional domains using an ordinal scale from 1 (worst) to 5 (best) to provide a combined health state score.
Six weeks post-vaccination
Circulating IL-1β analysis
Tidsramme: Three weeks after commencement of sirolimus (after administration of final dose of sirolimus)
Pre- and post-sirolimus circulating cytokine and chemokine analysis, measured as change in concentration of serum factor IL-1β from baseline to the end of sirolimus administration.
Three weeks after commencement of sirolimus (after administration of final dose of sirolimus)
Circulating IFN-α2 analysis
Tidsramme: Three weeks after commencement of sirolimus (after administration of final dose of sirolimus)
Pre- and post-sirolimus circulating cytokine and chemokine analysis, measured as change in concentration of serum factor IFN-α2 from baseline to the end of sirolimus administration.
Three weeks after commencement of sirolimus (after administration of final dose of sirolimus)
Circulating IFN-γ analysis
Tidsramme: Three weeks after commencement of sirolimus (after administration of final dose of sirolimus)
Pre- and post-sirolimus circulating cytokine and chemokine analysis, measured as change in concentration of serum factors IFN-γ from baseline to the end of sirolimus administration.
Three weeks after commencement of sirolimus (after administration of final dose of sirolimus)
Circulating TNF-α analysis
Tidsramme: Three weeks after commencement of sirolimus (after administration of final dose of sirolimus)
Pre- and post-sirolimus circulating cytokine and chemokine analysis, measured as change in concentration of serum factors TNF-α from baseline to the end of sirolimus administration.
Three weeks after commencement of sirolimus (after administration of final dose of sirolimus)
Circulating MCP-1 analysis
Tidsramme: Three weeks after commencement of sirolimus (after administration of final dose of sirolimus)
Pre- and post-sirolimus circulating cytokine and chemokine analysis, measured as change in concentration of serum factors MCP-1 from baseline to the end of sirolimus administration.
Three weeks after commencement of sirolimus (after administration of final dose of sirolimus)
Circulating IL-6 analysis
Tidsramme: Three weeks after commencement of sirolimus (after administration of final dose of sirolimus)
Pre- and post-sirolimus circulating cytokine and chemokine analysis, measured as change in concentration of serum factor IL-6 from baseline to the end of sirolimus administration.
Three weeks after commencement of sirolimus (after administration of final dose of sirolimus)
Circulating CXCL8 (IL-8)
Tidsramme: Three weeks after commencement of sirolimus (after administration of final dose of sirolimus)
Pre- and post-sirolimus circulating cytokine and chemokine analysis, measured as change in concentration of serum factor CXCL8 (IL-8) from baseline to the end of sirolimus administration.
Three weeks after commencement of sirolimus (after administration of final dose of sirolimus)
Circulating IL-10 analysis
Tidsramme: Three weeks after commencement of sirolimus (after administration of final dose of sirolimus)
Pre- and post-sirolimus circulating cytokine and chemokine analysis, measured as change in concentration of serum factor IL-10 from baseline to the end of sirolimus administration.
Three weeks after commencement of sirolimus (after administration of final dose of sirolimus)
Circulating IL-12p70 analysis
Tidsramme: Three weeks after commencement of sirolimus (after administration of final dose of sirolimus)
Pre- and post-sirolimus circulating cytokine and chemokine analysis, measured as change in concentration of serum factor IL-12p70 from baseline to the end of sirolimus administration.
Three weeks after commencement of sirolimus (after administration of final dose of sirolimus)
Circulating IL-17A analysis
Tidsramme: Three weeks after commencement of sirolimus (after administration of final dose of sirolimus)
Pre- and post-sirolimus circulating cytokine and chemokine analysis, measured as change in concentration of serum factors IL-17A from baseline to the end of sirolimus administration.
Three weeks after commencement of sirolimus (after administration of final dose of sirolimus)
Circulating IL-18 analysis
Tidsramme: Three weeks after commencement of sirolimus (after administration of final dose of sirolimus)
Pre- and post-sirolimus circulating cytokine and chemokine analysis, measured as change in concentration of serum factors IL-18 from baseline to the end of sirolimus administration.
Three weeks after commencement of sirolimus (after administration of final dose of sirolimus)
Circulating IL-23 analysis
Tidsramme: Three weeks after commencement of sirolimus (after administration of final dose of sirolimus)
Pre- and post-sirolimus circulating cytokine and chemokine analysis, measured as change in concentration of serum factors IL-23 from baseline to the end of sirolimus administration.
Three weeks after commencement of sirolimus (after administration of final dose of sirolimus)
Circulating IL-33 analysis
Tidsramme: Three weeks after commencement of sirolimus (after administration of final dose of sirolimus)
Pre- and post-sirolimus circulating cytokine and chemokine analysis, measured as change in concentration of serum factors IL-33 from baseline to the end of sirolimus administration.
Three weeks after commencement of sirolimus (after administration of final dose of sirolimus)
Circulating CRP analysis
Tidsramme: Three weeks after commencement of sirolimus (after administration of final dose of sirolimus)
Pre- and post-sirolimus circulating cytokine and chemokine analysis, measured as change in concentration of serum factors CRP from baseline to the end of sirolimus administration.
Three weeks after commencement of sirolimus (after administration of final dose of sirolimus)

Samarbeidspartnere og etterforskere

Det er her du vil finne personer og organisasjoner som er involvert i denne studien.

Sponsor

Central Adelaide Local Health Network Incorporated

Studierekorddatoer

Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.

Studer hoveddatoer

Studiestart (Antatt)

1. mai 2026

Primær fullføring (Antatt)

1. juli 2026

Studiet fullført (Antatt)

1. juli 2026

Datoer for studieregistrering

Først innsendt

6. mai 2026

Først innsendt som oppfylte QC-kriteriene

11. mai 2026

Først lagt ut (Faktiske)

14. mai 2026

Oppdateringer av studieposter

Sist oppdatering lagt ut (Faktiske)

14. mai 2026

Siste oppdatering sendt inn som oppfylte QC-kriteriene

11. mai 2026

Sist bekreftet

1. mai 2026

Mer informasjon

Begreper knyttet til denne studien

Nøkkelord

Ytterligere relevante MeSH-vilkår

Andre studie-ID-numre

  • 2025/HRE00483

Plan for individuelle deltakerdata (IPD)

Planlegger du å dele individuelle deltakerdata (IPD)?

JA

IPD-planbeskrivelse

Anonymized patient-level data created for the study will be available in a persistent repository upon publication. Data will be uploaded to figshare.com.

IPD-delingstidsramme

Anonymized IPD will be made available in a persistent repository from the date of publication of trial findings.

Tilgangskriterier for IPD-deling

Anonymized IPD will be publicly accessible by download from the persistent repository.

Legemiddel- og utstyrsinformasjon, studiedokumenter

Studerer et amerikansk FDA-regulert medikamentprodukt

Nei

Studerer et amerikansk FDA-regulert enhetsprodukt

Nei

produkt produsert i og eksportert fra USA

Nei

Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .

Abonnere